Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...